151
Participants
Start Date
March 31, 2013
Primary Completion Date
September 10, 2016
Study Completion Date
November 7, 2017
Treatment Group (transvenous stimulation of the phrenic nerve)
device implant, optimal medical therapy and device initiation 1 month post implant.
Control Group (Optimal Medical Therapy)
device implant, optimal medical therapy and delayed device initiation (7 months post device implant)
Lancaster General Hospital, Lancaster
Hospital of University of Pennsylvania, Philadelphia
University of Maryland, Baltimore, Baltimore
Johns Hopkins Bayview Medical Center, Baltimore
Virginia Commonwealth University, Richmond
Forsyth Medical Center - Novant, Winston-Salem
Novant Medical Group, Inc. Presbyterian Sleep Health Charlotte, Charlotte
University of Florida - Jacksonville, Jacksonville
Stern Cardiovascular, Memphis
Ohio State University, Columbus
The Lindner Center for Research and Education at Christ Hospital, Cincinnati
Detroit Clinical Research Center, Farmington Hills
Spectrum Health, Grand Rapids
Marshfield Clinic, Marshfield
United Heart and Vascular (Allina), Saint Paul
Advocate Medical Group, Downers Grove
Edward Hospital-Advocate Medical Group, Naperville
Washington University, St Louis
Mid America Heart Institute, Kansas City
Bryan Heart, Lincoln
Methodist Healthcare System, San Antonio
Keck Hospital of USC, Los Angeles
Cooper Health System, Cherry Hill
Bad Oeynhausen- Heart & Diabetes Center, Bad Oeynhausen
Charite Medical School, Campus Virchow-Klinikum, Berlin
Bernau-Herzzentruym Brandenburg, Bernau
Bielefeld-Klinikun, Bielefeld
Hamburg: Universitares Herzzentrum, Hamburg
Ambulantes Herzzentrum-Kassel, Kassel
Fourth Military Hospital, Wroclaw
Respicardia, Inc.
INDUSTRY